Ready-to-use food (RUF) is increasingly used for nutritional therapy in HIV-infected individuals. However, practical guidance advising nutrition care to HIV-infected adolescents is lacking, so that little is known about the acceptability of such therapy in this vulnerable population.
This study assesses the overall acceptability and perception of a RUF-based therapy and risk factors associated with sub-optimal RUF intake in HIV-infected undernourished adolescents in Senegal.Participants 5 to 18 years of age with acute malnutrition were enrolled in 12 HIV clinics in Senegal. Participants were provided with imported RUF, according to WHO prescription weight- and age-bands (2009), until recovery or for a maximum of 9-12 months. Malnutrition and recovery were defined according to WHO growth standards.
Adherence was assessed fortnightly by self-reported RUF intake over the period. Sub-optimal RUF intake was defined as when consumption of the RUF provision was < 50%. RUF therapy acceptability and perceptions were assessed using a structured questionnaire at week 2 and focus group discussions (FGDs) at the end of the study. Factors associated with sub-optimal RUF intake at week 2 were identified using a stepwise logistic regression model.
We enrolled 173 participants, with a median age of 12.5 years (Interquartile range: 9.5-14.9), of whom 61% recovered from malnutrition within the study period.
Median follow-up duration was 66 days (21-224). RUF consumption was stable, varying between 64 and 57% of the RUF provided, throughout the follow-up. At week 2, sub-optimal RUF intake was observed in 31% of participants. Dislike of the taste of RUF (aOR = 5.0, 95% CI: 2.0-12.3), HIV non-disclosure (5.1, 1.9-13.9) and food insecurity (2.8, 1.1-7.2) were the major risk factors associated with sub-optimal RUF intake at week 2.
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC941259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC941259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC801259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC801259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC811259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC811259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC701259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC701259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC881259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC881259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC051259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC051259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC041259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC041259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC401259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC401259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCB1259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCB1259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCAP1259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCAP1259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCA1259-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), APC conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCR1259-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), RPE conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCP1259-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNUM1259-50 | Biotium | 50uL | 474 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), 1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCH1259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNCH1259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNUB1259-100 | Biotium | 100uL | 250.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Concentration: 0.2mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNUB1259-500 | Biotium | 500uL | 549.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Concentration: 0.2mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC611259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC611259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC551259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC551259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC431259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC431259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC681259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC681259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC471259-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
|||
| BNC471259-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody, Clone: NK/804 |
|||
| AMM00761G | Leading Biology | 7 ml | 580.8 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker). The antibodies are raised in Mouse and are from clone NK/804. This antibody is applicable in IHC, IF |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody, Clone: NK-1 |
|||
| AMM00752G | Leading Biology | 7 ml | 580.8 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker). The antibodies are raised in Mouse and are from clone NK-1. This antibody is applicable in IHC, IF |
|||
CD57 / B3GAT1 (Natural Killer Cell Marker); Clone HNK-1 & NK-1 (Concentrate) |
|||
| RA0357-C.1 | ScyTek Laboratories | 0.1 ml | 150 EUR |
CD57 / B3GAT1 (Natural Killer Cell Marker); Clone HNK-1 & NK-1 (Concentrate) |
|||
| RA0357-C.5 | ScyTek Laboratories | 0.5 ml | 296.4 EUR |
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody, Clone: HNK-1 + NK-1 |
|||
| AMM00758G | Leading Biology | 7 ml | 580.8 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker). The antibodies are raised in Mouse and are from clone HNK-1 + NK-1. This antibody is applicable in IHC, IF |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC942403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC942403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC802403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC802403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC702403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC702403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC882403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC882403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC812403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC812403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC402403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC402403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC052403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC052403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC042403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC042403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCAP2403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCAP2403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCA2403-250 | Biotium | 250uL | 472.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), APC conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCP2403-250 | Biotium | 250uL | 472.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCR2403-250 | Biotium | 250uL | 472.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), RPE conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCH2403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCH2403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCB2403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNCB2403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNUB2403-100 | Biotium | 100uL | 316.8 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Concentration: 0.2mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNUB2403-50 | Biotium | 50uL | 486 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), 1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNUB2403-500 | Biotium | 500uL | 615.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), Concentration: 0.2mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC472403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC472403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC552403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC552403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC612403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC612403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC432403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC432403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC682403-100 | Biotium | 100uL | 279.6 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403) Antibody |
|||
| BNC682403-500 | Biotium | 500uL | 654 EUR |
|
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker) (GZMB/2403), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody - With BSA and Azide, Clone: NK/804 |
|||
| AMM00762G | Leading Biology | 0.05mg | 475.2 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone NK/804. This antibody is applicable in IHC, IF |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody - With BSA and Azide, Clone: NK-1 |
|||
| AMM00753G | Leading Biology | 0.05mg | 475.2 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone NK-1. This antibody is applicable in IHC, IF |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody - Without BSA and Azide, Clone: NK-1 |
|||
| AMM00754G | Leading Biology | 0.1mg | 580.8 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone NK-1. This antibody is applicable in IHC, IF |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody - Without BSA and Azide, Clone: NK/804 |
|||
| AMM00763G | Leading Biology | 0.1mg | 580.8 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone NK/804. This antibody is applicable in IHC, IF |
|||
Plasma Cell Marker Antibody |
|||
| V9116-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: It recognizes an intra-cytoplasmic antigen, which shows a very high degree of specificity for plasma cells. This antigen is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This mAb superbly recognizes normal and neoplastic plasma cells in routine formalin-fixed, paraffin-embedded tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. |
|||
Plasma Cell Marker Antibody |
|||
| V9116-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
|
Description: It recognizes an intra-cytoplasmic antigen, which shows a very high degree of specificity for plasma cells. This antigen is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This mAb superbly recognizes normal and neoplastic plasma cells in routine formalin-fixed, paraffin-embedded tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. |
|||
Plasma Cell Marker Antibody |
|||
| V9116IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
|
Description: It recognizes an intra-cytoplasmic antigen, which shows a very high degree of specificity for plasma cells. This antigen is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This mAb superbly recognizes normal and neoplastic plasma cells in routine formalin-fixed, paraffin-embedded tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. |
|||
Plasma Cell Marker Antibody |
|||
| V9116SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: It recognizes an intra-cytoplasmic antigen, which shows a very high degree of specificity for plasma cells. This antigen is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This mAb superbly recognizes normal and neoplastic plasma cells in routine formalin-fixed, paraffin-embedded tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. |
|||
Plasma Cell Marker Antibody |
|||
| V2360-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: This antibody recognizes an intra-cytoplasmic marker antigen which shows a very high degree of specificity for plasma cells. This marker protein is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This marker antibody superbly recognizes normal and neoplastic plasma cells in routine formalin/paraffin tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. Note that this plasma cell marker antibody is not suitable for staining frozen tissues. |
|||
Plasma Cell Marker Antibody |
|||
| V2360-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
|
Description: This antibody recognizes an intra-cytoplasmic marker antigen which shows a very high degree of specificity for plasma cells. This marker protein is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This marker antibody superbly recognizes normal and neoplastic plasma cells in routine formalin/paraffin tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. Note that this plasma cell marker antibody is not suitable for staining frozen tissues. |
|||
Plasma Cell Marker Antibody |
|||
| V2360IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
|
Description: This antibody recognizes an intra-cytoplasmic marker antigen which shows a very high degree of specificity for plasma cells. This marker protein is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This marker antibody superbly recognizes normal and neoplastic plasma cells in routine formalin/paraffin tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. Note that this plasma cell marker antibody is not suitable for staining frozen tissues. |
|||
Plasma Cell Marker Antibody |
|||
| V2360SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: This antibody recognizes an intra-cytoplasmic marker antigen which shows a very high degree of specificity for plasma cells. This marker protein is present in normal as well as neoplastic plasma cells. Plasma cells, which are large lymphocytes derived from an antigen-specific B cell, secrete antibodies and are responsible for humoral immunity. Plasma cells differentiate from B cells upon stimulation by CD4+ lymphocytes. The B cell acts as an antigen-presenting cell (APC), consuming an offending pathogen, which is taken up by the B cell by phagocytosis and broken down within proteosomes. Plasma cells contain basophilic cytoplasm; their nucleus contains heterochromatin organized in a characteristic cartwheel arrangement. This marker antibody superbly recognizes normal and neoplastic plasma cells in routine formalin/paraffin tissue sections. It is of potential value in identifying myeloma or plasmacytoma in bone marrow or other tissues. It also helps differentiate lympho-plasmacytoid lymphoma from lymphocytic and follicular lymphoma. Note that this plasma cell marker antibody is not suitable for staining frozen tissues. |
|||
Myeloid Cell Marker Antibody |
|||
| V9118-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: SPM298 Ab reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. Markers of myeloid cells are useful in the identification of different levels of cellular differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V9118-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
|
Description: SPM298 Ab reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. Markers of myeloid cells are useful in the identification of different levels of cellular differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V9118IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
|
Description: SPM298 Ab reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. Markers of myeloid cells are useful in the identification of different levels of cellular differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V9118SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: SPM298 Ab reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. Markers of myeloid cells are useful in the identification of different levels of cellular differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V2356-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: This antibody recognizes a 183kDa protein with DNA-binding characteristics, which is identified as a myeloid cell specific antigen. Clone BM-1 antibody reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. This type of marker is useful in the identification of different levels of cellular differentiation. BM-1 and BM-2 antibodies react with early precursor and mature forms of human myeloid cells. This mAb is useful in the identification of myelogenous leukemias, distinguishing granulocytic sarcomas from lymphoid malignancies and also in the study of differentiation and transformation of human myeloid cells. The biological function of the marker protein is not clear, although it has been proposed that it may play a role in cell differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V2356-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
|
Description: This antibody recognizes a 183kDa protein with DNA-binding characteristics, which is identified as a myeloid cell specific antigen. Clone BM-1 antibody reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. This type of marker is useful in the identification of different levels of cellular differentiation. BM-1 and BM-2 antibodies react with early precursor and mature forms of human myeloid cells. This mAb is useful in the identification of myelogenous leukemias, distinguishing granulocytic sarcomas from lymphoid malignancies and also in the study of differentiation and transformation of human myeloid cells. The biological function of the marker protein is not clear, although it has been proposed that it may play a role in cell differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V2356IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
|
Description: This antibody recognizes a 183kDa protein with DNA-binding characteristics, which is identified as a myeloid cell specific antigen. Clone BM-1 antibody reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. This type of marker is useful in the identification of different levels of cellular differentiation. BM-1 and BM-2 antibodies react with early precursor and mature forms of human myeloid cells. This mAb is useful in the identification of myelogenous leukemias, distinguishing granulocytic sarcomas from lymphoid malignancies and also in the study of differentiation and transformation of human myeloid cells. The biological function of the marker protein is not clear, although it has been proposed that it may play a role in cell differentiation. |
|||
Myeloid Cell Marker Antibody |
|||
| V2356SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: This antibody recognizes a 183kDa protein with DNA-binding characteristics, which is identified as a myeloid cell specific antigen. Clone BM-1 antibody reacts with myeloid precursor cells and granulocytes in bone marrow. Its antigen appears to be restricted to M2 and M3 acute myelogenous leukemia (AML) subtypes. This type of marker is useful in the identification of different levels of cellular differentiation. BM-1 and BM-2 antibodies react with early precursor and mature forms of human myeloid cells. This mAb is useful in the identification of myelogenous leukemias, distinguishing granulocytic sarcomas from lymphoid malignancies and also in the study of differentiation and transformation of human myeloid cells. The biological function of the marker protein is not clear, although it has been proposed that it may play a role in cell differentiation. |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody - With BSA and Azide, Clone: HNK-1 + NK-1 |
|||
| AMM00759G | Leading Biology | 0.05mg | 475.2 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone HNK-1 + NK-1. This antibody is applicable in IHC, IF |
|||
Monoclonal CD57 / B3GAT1 (Natural Killer Cell Marker) Antibody - Without BSA and Azide, Clone: HNK-1 + NK-1 |
|||
| AMM00760G | Leading Biology | 0.1mg | 580.8 EUR |
|
Description: A Monoclonal antibody against Human CD57 / B3GAT1 (Natural Killer Cell Marker) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone HNK-1 + NK-1. This antibody is applicable in IHC, IF |
|||
Desmin Antibody (Muscle cell marker) |
|||
| F43697-0.08ML | NSJ Bioreagents | 0.08 ml | 140.25 EUR |
|
Description: This gene encodes a muscle-specific class III intermediate filament. Homopolymers of this protein form a stable intracytoplasmic filamentous network connecting myofibrils to each other and to the plasma membrane. Mutations in this gene are associated with desmin-related myopathy, a familial cardiac and skeletal myopathy (CSM), and with distal myopathies. [provided by RefSeq]. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| F43697-0.4ML | NSJ Bioreagents | 0.4 ml | 322.15 EUR |
|
Description: This gene encodes a muscle-specific class III intermediate filament. Homopolymers of this protein form a stable intracytoplasmic filamentous network connecting myofibrils to each other and to the plasma membrane. Mutations in this gene are associated with desmin-related myopathy, a familial cardiac and skeletal myopathy (CSM), and with distal myopathies. [provided by RefSeq]. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| F48175-0.08ML | NSJ Bioreagents | 0.08 ml | 140.25 EUR |
|
Description: Desmin are class-III intermediate filaments found in muscle cells. In adult striated muscle they form a fibrous network connecting myofibrils to each other and to the plasma membrane from the periphery of the Z-line structures. [UniProt] |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V3195-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain a-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V3195-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain a-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V3195SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain a-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V7478-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain alpha-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V7478-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain alpha-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V7478IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain alpha-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Desmin Antibody (Muscle cell marker) |
|||
| V7478SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
|
Description: Cytoskeletal intermediate filaments (IFs) constitute a diverse group of proteins that are expressed in a highly tissue-specific manner. IFs are constructed from two-chain alpha-helical coiled-coil molecules arranged on an imperfect helical lattice, and have been widely used as markers for distinguishing individual cell types within a tissue and identifying the origins of metastatic tumors. Vimentin is an IF general marker of cells originating in the mesenchyme. Vimentin and Desmin, a related class III IF, are both expressed during skeletal muscle development. Desmin, a 469 amino acid protein found near the Z line in sarcomeres, is expressed more frequently in adult differentiated state tissues. Anti-desmin detects cells of normal smooth, skeletal, and cardiac muscles. Antibody reacts with leiomyomas, leiomyosarcoma, rhabdomyomas, rhabdomyosarcoma, and perivascular cells of glomus tumors of the skin. |
|||
Polyclonal Granzyme B (NK/T-Cell Lymphoma Marker) Antibody - With BSA and Azide |
|||
| APR00543G | Leading Biology | 50 ug | 475.2 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Granzyme B (NK/T-Cell Lymphoma Marker) - With BSA and Azide. This antibody is tested and proven to work in the following applications: |
|||
Polyclonal Granzyme B (NK/T-Cell Lymphoma Marker) Antibody - Without BSA and Azide |
|||
| APR00544G | Leading Biology | 0.1mg | 580.8 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Granzyme B (NK/T-Cell Lymphoma Marker) - Without BSA and Azide. This antibody is tested and proven to work in the following applications: |
|||
Myeloid Cell Marker (Macrophage / Granulocyte Marker); Clone BM-1 (Concentrate) |
|||
| RA0400-C.1 | ScyTek Laboratories | 0.1 ml | 150 EUR |
Myeloid Cell Marker (Macrophage / Granulocyte Marker); Clone BM-1 (Concentrate) |
|||
| RA0400-C.5 | ScyTek Laboratories | 0.5 ml | 360 EUR |
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCA0047-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), APC conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC810047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC810047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC800047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC800047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF680 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC940047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC940047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC880047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC880047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC430047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC430047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF543 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC400047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC400047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF640R conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC050047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC050047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCB0047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCB0047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCAP0047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCAP0047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCR0047-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), RPE conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNUB0047-100 | Biotium | 100uL | 250.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Concentration: 0.2mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNUB0047-500 | Biotium | 500uL | 549.6 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Concentration: 0.2mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCP0047-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCH0047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNCH0047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNUM0047-50 | Biotium | 50uL | 474 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), 1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC040047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC040047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC550047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC550047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF555 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC610047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC610047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF660R conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC680047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC680047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC470047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC470047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC700047-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF770 conjugate, Concentration: 0.1mg/mL |
|||
Plasma Cell Marker(LIV3G11 (7B18)) Antibody |
|||
| BNC700047-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Plasma Cell Marker(LIV3G11 (7B18)), CF770 conjugate, Concentration: 0.1mg/mL |
|||
CD5 (Mantel Cell Lymphoma Marker); 4C7 |
|||
| A20090 | ScyTek Laboratories | 2 ml | 216 EUR |
CD5 (Mantel Cell Lymphoma Marker); 4C7 |
|||
| A00090.0025 | ScyTek Laboratories | 25 ml | 1150.8 EUR |
CD5 (Mantel Cell Lymphoma Marker); 4C7 |
|||
| A00090.050 | ScyTek Laboratories | 50 ml | 1806 EUR |
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC941491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF594 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC941491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF594 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC941492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF594 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC941492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF594 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC801491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF680 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC801491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF680 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC801492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF680 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC801492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF680 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC811491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF680R conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC811491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF680R conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC811492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF680R conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC811492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF680R conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC701491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF770 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC701491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF770 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC701492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF770 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC701492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF770 conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC881491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF488A conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC881491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF488A conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC881492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF488A conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC881492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF488A conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC051491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF405M conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC051491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF405M conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC051492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF405M conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC051492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF405M conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC041491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF405S conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC041491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF405S conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC041492-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF405S conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1492) Antibody |
|||
| BNC041492-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1492),CF405S conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC401491-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF640R conjugate, Concentration: 0.1mg/mL |
|||
PAX8 (Renal Cell Marker) (PAX8/1491) Antibody |
|||
| BNC401491-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against PAX8 (Renal Cell Marker) (PAX8/1491),CF640R conjugate, Concentration: 0.1mg/mL |
|||
FGDs showed that the need to hide from others to avoid sharing and undesirable effects were other constraints on RUF feeding.This study revealed several factors reducing the acceptability and adherence to RUF therapy based on WHO guidelines in HIV-infected adolescents.
Tailoring prescription guidance and empowering young patients in their care are crucial levers for improving the acceptability of RUF-based therapy in routine care.ClinicalTrials.gov identifier